Coating Place Secures Investment from 1315 Capital for Microencapsulation Solutions
Fifty years deep and still coating the future. Coating Place just secured a strategic growth investment from 1315 Capital, and if that sounds like a quiet headline, you are missing the pressure building underneath the surface. This is not a victory lap. This is a company with half a century of scar tissue deciding the timing is finally right to press the accelerator without losing control.
Founded in 1976 by Harlan S. Hall, Coating Place was built on the back of Dr. Dale E. Wurster's fluid bed coating technology, the kind of invention that never chases applause but ends up holding entire industries together. Verona, Wisconsin became the proving ground for a company that chose precision over volume, patience over shortcuts, and process over promises. Fifty years later, that mindset is still baked into every run.
When Tim Breunig and Kendall Breunig acquired majority ownership in 1999, the mandate was simple and ruthless: build it right or do not build it at all. Proprietary equipment. Inhouse engineering. Linear scalability that actually works. From 10 grams in R&D to 800 kg in commercial production with no reformulation and no surprises. That is not a slide deck claim. That is execution under GMP conditions.
Coating Place operates more than 350,000 sq. ft. across Verona and Sauk City, running 24 proprietary Wurster units supporting pharma, nutraceutical, animal health, and industrial customers who cannot afford guesswork. FDA and Health Canada registered. DEA licensed Schedule I-V. NSF certified. This is what long term credibility looks like when regulators, auditors, and customers all show up with receipts.
Enter 1315 Capital, a healthcare focused investment firm with $1B+ AUM and a clear bias toward specialized platforms that scale without losing their edge. Matthew Reber recognized what experienced operators see quickly: defensible systems, real technical depth, and a leadership team that understands growth is a discipline, not a vibe. This is growth equity, not a teardown. Partnership, not noise.
The capital is about capacity, technology, and reach. More coating capability. More control. More room for complex modified release products that demand rigor, not slogans. The global CDMO market is expanding at ~7% CAGR, but the winners will not be the loudest voices. They will be the ones who stay calm when molecules get difficult and regulators get curious.
Tim Breunig, Jason Corrao, Jamie Iserloth, Jared McDonald, Charles Frey, Frederick Schulze, Rishabh Sachdeva, Nicole Swails, Jeremy Breunig, and the teams in Verona and Sauk City did not stumble into this moment. They compounded into it. Fifty years of process discipline just met growth capital with patience.